Alpha interferon therapy in Danish haemophiliac patients with chronic hepatitis C: Results of a randomized controlled open label study comparing two different maintenance regimens following standard interferon-alpha-2b treatment

Haemophilia

Volumn 4, Issue 1, 1998, Pages 25-32

  Laursen, A L ^a,f   Scheibel, E ^b   Ingerslev, J ^a   Clausen, N C ^a   Wantzin, P ^c   Ostergaard L ^a   Schou, G ^d   Black, F T ^a   Krogsgaard, K ^e  

^a AARHUS UNIVERSITY   (Denmark)

^b University of Copenhagen   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d NONE

^e Capital Region   (Denmark)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Alpha interferon treatment; Chronic hepatitis C; Haemophiliac patients; Randomized controlled trial

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ANTIVIRUS AGENT;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; DRUG ADMINISTRATION; FEMALE; HEMOPHILIA A; HEPATITIS C; HUMAN; MALE; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DENMARK; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOPHILIA A; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED;

EID: 0031598333     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1998.00141.x     Document Type: Article

References (24)

1. Watson HG, Ludlam CA, Rebus S, et al. Use of several second generation serological assays to determine the true prevalence of hepatitis C virus infection in haemophiliacs treated with non-virus inactivated factor VIII and IX concentrates. Br J Haematol 1992; 80: 514-8.
2. Tremolada F, Casarin C, Alberti A, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992; 16: 273-81.
3. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-801.
4. Yano M, Yatsuhashi H, Inoue O, Inokuchi K, Koga M. Epidemiology and long term prognosis of hepatitis C virus infection in Japan. Gut 1993; suppl: S13-6.
5. Aledort LM, Levine PH, Hilgartner M, et al. A study of liver biopsies and liver diseases among hemophiliacs. Blood 1985; 66: 357-72.
6. Bresters D, Cuypers HTM, Reesink HW, et al. Comparison of quantitative cDNA-PCR with the branched DNA hybridization assay for monitoring plasma hepatitis c RNA levels in haemophilia patients participating in a controlled interferon trial. J Med Virol 1994; 43: 262-8.
7. Makris M, Preston FE, Triger DR, Underwood JCE, Westlake L, Adelman MI. A randomized controlled trial of recombinant interferon-α in chronic hepatitis C in haemophiliacs. Blood 1991; 78: 1672-7.
8. Bresters D, Mauser-Bunschoten EP, Cuypers HTM, et al. Long term treatment of chronic hepatitis C with interferon alfa-2b: disappearance of HCV-RNA in a pilot study of eight haemophilia patients. Gut 1993; 34 (2 suppl.): S124-5.
9. Davis GL. Recombinant alpha-interferon treatment of non-A and non-B (type C) hepatitis: review of studies and recommendations for treatment. J Hepatol 1990; 11: suppl 1: S72-7.
10. Hakozaki Y, Shirahama T, Katou M, Nakagawa K, Oba K, Mitamura KL. A controlled study to determine the optimal dose treatment of interferon-alpha 2b in chronic hepatitis C. Am J Gastroenterol 1995; 90: 1246-9.
11. Chemello L, Bonetti P, Cacaletto L, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22: 700-6.
12. Hwang SJ, Chan CY, Lu RH, Wu JC, Lee SD. Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chinese patients with chronic hepatitis C. J Interferon Cytokine Res 1995; 15: 611-6.
13. Bjøro K, Kratup H, Bell H, et al. Two dose regimens of recombinant interferon-alpha-2b in chronic hepatitis C infection. Scand J Gastroenterol 1995; 30: 1119-24.
14. Dusheiko G, Schmilovitz-Weiss H, Brown D, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994; 19: 13-8.
15. Devereux H, Telfer P, Dusheiko G, Lee C. Hepatitis C genotypes in haemophiliac patients treated with alpha-interferon. J Med Virol 1995; 45: 284-7.
16. Widell A, Shev S, Mansson S, et al. Genotyping of hepatitis C virus isolates by a modified polymerase chain reaction assay using specific primers: epidemiological applications. J Med Virol 1994; 44: 272-9.
17. Causse X, Godinot H, Chellier M, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991; 101: 497-502.
18. Simons JN, Leary TP, Dawson GJ, et al. Isolation of novel virus-like sequences associated with human hepatitis. Nature Med 1995; 1: 564-9.
19. Bosch O, Tapia L, Quiroga JA, Carreno V. An escalating dose regime of recombinant interferon-alpha 2A in the treatment of chronic hepatitis C. J Hepatol 1993; 17: 146-9.
20. Hakozaki Y, Shirahama T, Katou M, Nakagawa K, Oba K, Mitamura K. A controlled study to determine the optimal dose regimen of interferon-alpha 2b in chronic hepatitis C. Am J Gastroenterol 1995; 90: 1246-9.
21. Piciotta A, Callea F, Varagona G, et al. Lymphoblastoid interferon therapy in chronic hepatitis C: biochemical, virological and histological evaluation of two different doses. Liver 1995; 15: 20-4.
22. Benelux Multicentre Trial Study Group. Benelux multicentre trial of alpha interferon treatment for chronic hepatitis C: standard v high dose treatment monitored by biochemical and virological markers (interim analysis). Gut 1993; 34 (2 suppl.): S119-20.
23. Metreau JM, and the French Group for the study of NANB/ C chronic hepatitis treatment. Results of long term interferon treatment in non A and non B/C chronic active hepatitis. Gut 1993; 34 (2 suppl.): S112-3.
24. Yamada G, Takatani M, Kishi F, et al. Efficacy of interferon alpha therapy in chronic hepatitis C in patients depends primarily on hepatitis C virus RNA level. Hepatology 1995; 22: 1351-4.